ICI therapy has proven to be a useful treatment for carcinoma [43–45], and we observed that the risk score was negatively correlated with the immune checkpoints CTLA4, ICOS, and PDCD1, suggesting that the sensitivity to immunotherapy may differ among subgroups. This evidence concerns the gene PDCD1 and carcinoma.